Anti-FGD5/ ZFYVE23 monoclonal antibody

Anti-FGD5/ ZFYVE23 antibody for FACS & in-vivo assay

Target products collectionGo to FGD5/FGD5 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2122-Ab-1/ GM-Tg-hg-MP2122-Ab-2Anti-Human FGD5 monoclonal antibodyHuman
GM-Tg-rg-MP2122-Ab-1/ GM-Tg-rg-MP2122-Ab-2Anti-Rat FGD5 monoclonal antibodyRat
GM-Tg-mg-MP2122-Ab-1/ GM-Tg-mg-MP2122-Ab-2Anti-Mouse FGD5 monoclonal antibodyMouse
GM-Tg-cynog-MP2122-Ab-1/ GM-Tg-cynog-MP2122-Ab-2Anti-Cynomolgus/ Rhesus macaque FGD5 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2122-Ab-1/ GM-Tg-felg-MP2122-Ab-2Anti-Feline FGD5 monoclonal antibodyFeline
GM-Tg-cang-MP2122-Ab-1/ GM-Tg-cang-MP2122-Ab-2Anti-Canine FGD5 monoclonal antibodyCanine
GM-Tg-bovg-MP2122-Ab-1/ GM-Tg-bovg-MP2122-Ab-2Anti-Bovine FGD5 monoclonal antibodyBovine
GM-Tg-equg-MP2122-Ab-1/ GM-Tg-equg-MP2122-Ab-2Anti-Equine FGD5 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2122-Ab-1/ GM-Tg-hg-MP2122-Ab-2; GM-Tg-rg-MP2122-Ab-1/ GM-Tg-rg-MP2122-Ab-2;
GM-Tg-mg-MP2122-Ab-1/ GM-Tg-mg-MP2122-Ab-2; GM-Tg-cynog-MP2122-Ab-1/ GM-Tg-cynog-MP2122-Ab-2;
GM-Tg-felg-MP2122-Ab-1/ GM-Tg-felg-MP2122-Ab-2; GM-Tg-cang-MP2122-Ab-1/ GM-Tg-cang-MP2122-Ab-2;
GM-Tg-bovg-MP2122-Ab-1/ GM-Tg-bovg-MP2122-Ab-2; GM-Tg-equg-MP2122-Ab-1/ GM-Tg-equg-MP2122-Ab-2
Products NameAnti-FGD5 monoclonal antibody
Formatmab
Target NameFGD5
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-FGD5 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species FGD5/ ZFYVE23 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLV000021human FGD5 Lentivirus particle
    ORF Viral VectorpGMLV000021human FGD5 Lentivirus plasmid


    Target information

    Target IDGM-MP2122
    Target NameFGD5
    Gene ID152273,232237,362402,702022,484640,101100875,539766,100055962
    Gene Symbol and SynonymsC330025N11Rik,FGD5,mFLJ00274,ZFYVE23
    Uniprot AccessionQ6ZNL6
    Uniprot Entry NameFGD5_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000154783
    Target ClassificationN/A

    The target: FGD5, gene name: FGD5, also named as ZFYVE23. Predicted to enable guanyl-nucleotide exchange factor activity and small GTPase binding activity. Predicted to be involved in several processes, including filopodium assembly; regulation of GTPase activity; and regulation of cell shape. Located in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.